# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-06-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: modern shifted

## What we are working on

- He wants to know what the pain and the urinary symptoms mean, and to be told plainly **S**
- He wants to keep writing every morning and to carry on his duties as ambassador **S**
- He wants important discussions held in Spanish **S**

## Your goals

- Diagnosis, staging and a shared treatment decision within three weeks of the first visit. Target: 2026-06-15. Recorded outcome: Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake. **S**
- Bone pain controlled, with a pain score of 2 or less and sleep restored. Target: 2026-07-13. Recorded outcome: Pain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation. **S**
- PSA of 0.2 ng/mL or less within about seven months of starting treatment. Target: 2026-09-14. Recorded outcome: PSA 46.8 to 0.18 ng/mL at three months. **S**
- Blood pressure below 130/80 mm Hg on androgen deprivation. Target: 2026-10-05. Recorded outcome: 152/90 at four weeks on apalutamide; 128/78 at the annual wellness visit on amlodipine 10 mg. **S**
- Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk. Target: 2026-10-05. Recorded outcome: Denosumab given at four weeks after a dental check; vitamin D 28 ng/mL and rising; walking daily. **S**
- Keep his morning writing and his official duties through treatment. Target: 2026-10-05. Recorded outcome: Writing every morning; one week of official engagements postponed during radiotherapy. **S**

## What we agreed to do

- Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testing. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026) **S**
- Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CT. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026) **S**
- Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel control. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026) **S**
- Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official duties. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026) **S**
- Systemic therapy: apalutamide 240 mg daily from the consultation day and leuprolide 22.5 mg every twelve weeks from one week later, continuous; docetaxel not added for low-volume disease. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); Chi KN, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer (TITAN). N Engl J Med 2019;381(1):13-24 (2019); Kyriakopoulos CE, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2018;36(11):1080-1087 (2018) **S**
- Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation, for low-volume metastatic disease. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); Parker CC, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353-2366 (2018) **S**
- Germline genetic testing with pre-test counseling, and somatic testing of the biopsy tissue. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026) **S**
- Bone health on androgen deprivation: DXA and FRAX, cholecalciferol 2000 units a day, calcium 1000 to 1200 mg a day from food, weight-bearing exercise, a dental examination, then denosumab 60 mg every six months for high fracture risk; DXA again in one to two years. Guideline: Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); Smith MR, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2014;32(11):1143-1150 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026) **S**
- Monitoring on androgen deprivation and apalutamide: PSA and testosterone every three months, blood count and chemistry, TSH every four months, blood pressure at every visit, hemoglobin A1c and lipids, rash, falls, hot flashes, sexual health, fatigue, mood and cognition. Guideline: Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026) **S**
- Apalutamide rash: triamcinolone 0.1% cream twice daily for two weeks, cetirizine 10 mg daily, fragrance-free emollient, continue apalutamide; stop it and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skin. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); ERLEADA (apalutamide) tablets: prescribing information (2026) **S**
- Atorvastatin 20 mg daily for primary prevention, with a lipid panel and ALT in six to twelve weeks. Guideline: CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022) **S**

## Follow-up

- 2026-06-01: New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral **S**
- 2026-06-15: Two-week review with the medical oncology consultation the same day: biopsy and staging results, the diagnosis, shared decision on treatment, the start of apalutamide, genetic testing, and bone density **S**
- 2026-07-13: Four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan **S**
- 2026-09-14: Three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year **S**
- 2026-10-05: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
